

NEUROSTIMULATION: TECHNOLOGIES AND GLOBAL MARKETS



PHM149A
March 2014

Minal Patel
Project Analyst

ISBN: 1-56965-750-5



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

| TOPIC | PAGE NO. |
|---|----------|
| CHAPTER 1 INTRODUCTION | 2 |
| INTRODUCTION | 2 |
| STUDY GOALS AND OBJECTIVES | 3 |
| REASONS FOR DOING THE STUDY | 3 |
| SCOPE OF REPORT | 3 |
| INTENDED AUDIENCE | 4 |
| INFORMATION SOURCES | 4 |
| ANALYST'S CREDENTIALS | 4 |
| RELATED BCC RESEARCH REPORTS | 4 |
| BCC RESEARCH ONLINE SERVICES | 5 |
| DISCLAIMER | 5 |
| CHAPTER 2 SUMMARY | 7 |
| SUMMARY | 7 |
| <i>SUMMARY TABLE GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY, THROUGH 2018 (\$ MILLIONS)</i> | 8 |
| <i>SUMMARY FIGURE GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY, 2012-2018 (\$ MILLIONS)</i> | 8 |
| CHAPTER 3 OVERVIEW OF NEUROSTIMULATION DEVICES | 10 |
| MARKET TRENDS (TECHNOLOGIES) AND MARKET SHARE (KEY PLAYERS AND ENTRY LEVEL PLAYERS) | 10 |
| CHRONIC PAIN | 10 |
| <i>TABLE 1 CHRONIC PAIN NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS)</i> | 10 |
| <i>FIGURE 1 MARKET SHARE OF CHRONIC PAIN NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (%)</i> | 11 |
| HEARING LOSS | 12 |
| <i>TABLE 2 HEARING LOSS NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS)</i> | 13 |
| <i>FIGURE 2 MARKET SHARES OF HEARING LOSS NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (%)</i> | 13 |
| OVERACTIVE BLADDER | 14 |
| <i>TABLE 3 OVERACTIVE BLADDER NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS)</i> | 14 |
| EPILEPSY | 14 |
| <i>TABLE 4 EPILEPSY NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS)</i> | 15 |
| FOOT DROP | 15 |
| <i>TABLE 5 FOOT DROP NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS)</i> | 16 |
| GASTROINTESTINAL DISORDERS | 17 |
| <i>TABLE 6 GASTROINTESTINAL DISORDERS NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS)</i> | 18 |
| <i>FIGURE 3 MARKET SHARES OF GASTROINTESTINAL DISORDERS NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (%)</i> | 18 |
| RETINAL DEGENERATION | 19 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 7 RETINAL DEGENERATION NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS)</i> | 20 |
| POSITIVE MARKET IMPACT | 20 |
| INCREASING ACCEPTANCE OF NEUROSTIMULATION DEVICES FOR MULTIPLE APPLICATIONS | 20 |
| New Technological Advancements | 20 |
| NEUROSTIMULATION THERAPIES FILL THE VOID OR ARE USED IN CONJUNCTION WITH CURRENT TREATMENT OPTIONS | 21 |
| NEGATIVE MARKET IMPACT | 21 |
| CURRENT DEVICE RECALLS: EXPOSING RISKS OF NEUROSTIMULATION DEVICES | 21 |
| INVESTMENT AND FUNDING FOR NEW TECHNOLOGICAL ADVANCES | 21 |
| LACK OF PRODUCT HANDLING AND IMPLANTATION TRAINING | 22 |
| CHAPTER 4 MARKET FOR NEUROSTIMULATION DEVICES | 24 |
| NEUROSTIMULATION FOR PAIN MANAGEMENT | 24 |
| CHRONIC BACK PAIN | 24 |
| <i>FIGURE 4 DISTRIBUTION OF CHRONIC BACK PAIN INJURY/ILLNESS REQUIRING DAYS MISSED FROM WORK BY CONDITION, 2011 (INCIDENCE RATE)</i> | 24 |
| <i>FIGURE 5 DISTRIBUTION OF SPRAINS, STRAINS AND TEARS REQUIRING ABSENCES FROM WORK BY BODY PART, 2011 (%)</i> | 25 |
| <i>FIGURE 6 DISTRIBUTION OF BACK INJURY INCIDENT RATES BY AGE GROUP, 2011</i> | 26 |
| <i>FIGURE 7 DISTRIBUTION OF INCIDENCE RATES OF SORENESS INCLUDING BACK PAIN BY AGE GROUP, 2011</i> | 27 |
| <i>TABLE 8 PREMARKET APPROVALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 28 |
| <i>TABLE 9 PREMARKET NOTIFICATIONS (510K) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 29 |
| <i>TABLE 10 CLINICAL TRIALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 29 |
| CHRONIC MIGRAINE | 29 |
| <i>FIGURE 8 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS INCLUDING MIGRAINE, 2005 (%)</i> | 30 |
| <i>FIGURE 9 DISTRIBUTION OF MIGRAINE INCIDENCE RATES BY AGE GROUP, 2011</i> | 31 |
| <i>TABLE 11 CLINICAL TRIALS UNDERWAY FOR CHRONIC MIGRAINE-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 32 |
| FAILED BACK SURGERY SYNDROME | 32 |
| <i>TABLE 12 PREMARKET APPROVALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 33 |
| <i>TABLE 13 CLINICAL TRIALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 33 |
| CHRONIC INTRACTABLE PAIN | 33 |
| <i>TABLE 14 PREMARKET APPROVALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 34 |
| <i>TABLE 15 CLINICAL TRIALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 34 |
| Patents | 34 |
| <i>TABLE 16 NEUROSTIMULATION AND PAIN PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013</i> | 35 |
| NEUROSTIMULATION FOR MOVEMENT DISORDERS | 35 |
| PARKINSON'S DISEASE | 35 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>FIGURE 10 GLOBAL PREVALENCE OF PARKINSON'S DISEASE, 2010 (MILLIONS)</i> | 35 |
| <i>FIGURE 11 GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, 2004 (%)</i> | 36 |
| <i>FIGURE 12 GLOBAL DEATHS OF MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, 2004 (%)</i> | 37 |
| <i>FIGURE 13 GLOBAL DEATHS OF FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, 2004 (%)</i> | 38 |
| <i>FIGURE 14 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2005 (%)</i> | 39 |
| <i>FIGURE 15 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2005 (%)</i> | 40 |
| <i>FIGURE 16 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2005 (%)</i> | 41 |
| <i>FIGURE 17 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2005 (%)</i> | 42 |
| <i>TABLE 17 PREMARKET APPROVALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 43 |
| <i>TABLE 18 CLINICAL TRIALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 43 |
| Patents | 44 |
| <i>TABLE 19 PATENTS FOR NEUROSTIMULATION AND PARKINSON'S APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 (NUMBER)</i> | 44 |
| DYSTONIA | 44 |
| <i>TABLE 20 PREMARKET APPROVALS FOR DYSTONIA-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 45 |
| <i>TABLE 21 CLINICAL TRIALS FOR DYSTONIA-ASSOCIATED DEEP NEUROSTIMULATION DEVICES</i> | 45 |
| Patents | 45 |
| <i>TABLE 22 NEUROSTIMULATION AND DYSTONIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 (NUMBER)</i> | 46 |
| ESSENTIAL TREMOR | 46 |
| <i>TABLE 23 PREMARKET APPROVALS FOR ESSENTIAL TREMOR-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 46 |
| <i>TABLE 24 CLINICAL TRIALS FOR ESSENTIAL TREMOR-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES</i> | 47 |
| Patents | 47 |
| <i>TABLE 25 NEUROSTIMULATION AND ESSENTIAL TREMOR PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 (NUMBER)</i> | 47 |
| EPILEPSY | 47 |
| <i>TABLE 26 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS, 2005 (%)</i> | 48 |
| <i>TABLE 27 GLOBAL DISTRIBUTION OF RANKINGS FOR EPILEPSY BY REGION, 2010</i> | 48 |
| <i>TABLE 28 GLOBAL PREVALENCE OF EPILEPSY (MILLIONS)</i> | 49 |
| <i>TABLE 29 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2005</i> | 49 |
| <i>TABLE 30 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2005 (%)</i> | 50 |
| <i>FIGURE 18 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2005</i> | 50 |
| <i>TABLE 31 GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, 2004 (%)</i> | 52 |

| TOPIC | PAGE NO. |
|---|-----------------|
| TABLE 32 GLOBAL DEATHS OF MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2004 (%) | 52 |
| TABLE 33 GLOBAL DEATHS OF FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2004 (%) | 53 |
| TABLE 34 PREMARKET APPROVALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES | 54 |
| TABLE 35 PREMARKET NOTIFICATION (510K) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES | 54 |
| TABLE 36 CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES | 54 |
| TABLE 37 CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED VAGAL NERVE NEUROSTIMULATION DEVICES | 54 |
| Patents | 55 |
| TABLE 38 NEUROSTIMULATION AND EPILEPSY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 (NUMBER) | 55 |
| NEUROSTIMULATION FOR NEUROPSYCHIATRIC DISORDERS | 55 |
| TABLE 39 GLOBAL DEATHS IN THE MALE POPULATION BY LEADING CAUSE GROUP, 2004 (%) | 56 |
| TABLE 40 GLOBAL DEATHS IN THE FEMALE POPULATION BY LEADING CAUSE GROUP, 2004 (%) | 56 |
| FIGURE 19 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006 (%) | 57 |
| SCHIZOPHRENIA | 58 |
| TABLE 41 GLOBAL RANKING OF SCHIZOPHRENIA BY REGION, 2010 | 58 |
| FIGURE 20 GLOBAL PREVALENCE OF SCHIZOPHRENIA, 2004 (%) | 58 |
| FIGURE 21 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%) | 59 |
| FIGURE 22 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%) | 60 |
| FIGURE 23 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%) | 61 |
| TABLE 42 GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING SCHIZOPHRENIA, 2010 (%) | 63 |
| TABLE 43 GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 63 |
| TABLE 44 GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 64 |
| TABLE 45 CLINICAL TRIALS FOR SCHIZOPHRENIA-ASSOCIATED NEUROSTIMULATION DEVICES | 65 |
| Patents | 65 |
| TABLE 46 NEUROSTIMULATION AND SCHIZOPHRENIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 65 |
| OBSESSIVE-COMPULSIVE DISORDER (OCD)/TOURETTE SYNDROME | 66 |
| TABLE 47 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%) | 66 |
| TABLE 48 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%) | 67 |
| TABLE 49 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%) | 67 |
| TABLE 50 DISTRIBUTION OF DALYS FOR OCD IN MALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006 | 68 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 51 DISTRIBUTION OF DALYS FOR OCD IN FEMALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006</i> | 68 |
| <i>TABLE 52 CLINICAL TRIALS FOR OCD-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES</i> | 68 |
| <i>TABLE 53 CLINICAL TRIALS FOR TOURETTE SYNDROME-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES</i> | 69 |
| Patents | 69 |
| <i>TABLE 54 NEUROSTIMULATION AND OCD PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013</i> | 70 |
| ALZHEIMER'S DISEASE (DEMENTIA) | 70 |
| <i>TABLE 55 GLOBAL PREVALENCE OF ALZHEIMER'S DISEASE, 2006 (MILLIONS)</i> | 70 |
| <i>TABLE 56 RANKING OF MORTALITY DUE TO ALZHEIMER'S IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010</i> | 71 |
| <i>FIGURE 24 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)</i> | 71 |
| <i>FIGURE 25 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%)</i> | 72 |
| <i>FIGURE 26 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%)</i> | 73 |
| <i>TABLE 57 GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, 2010 (%)</i> | 74 |
| <i>FIGURE 27 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006 (%)</i> | 75 |
| <i>TABLE 58 GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%)</i> | 76 |
| <i>TABLE 59 GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%)</i> | 76 |
| <i>TABLE 60 CLINICAL TRIALS FOR ALZHEIMER'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 77 |
| Patents | 78 |
| <i>TABLE 61 NEUROSTIMULATION AND ALZHEIMER'S PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013</i> | 78 |
| ANOREXIA NERVOSA (EATING DISORDER) | 78 |
| <i>TABLE 62 CLINICAL TRIALS FOR ANOREXIA NERVOSA-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES</i> | 79 |
| Patents | 79 |
| <i>TABLE 63 NEUROSTIMULATION AND ANOREXIA NERVOSA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013</i> | 79 |
| MOOD DISORDER (BIPOLAR DISORDER AND DEPRESSION) | 80 |
| Bipolar Disorder | 80 |
| <i>TABLE 64 DISTRIBUTION OF RANKINGS FOR BIPOLAR DISORDER BY GLOBAL REGIONS, 2010 (RANK)</i> | 80 |
| <i>TABLE 65 GLOBAL PREVALENCE OF BIPOLAR DISORDER, 2004 (MILLIONS)</i> | 81 |
| <i>TABLE 66 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006</i> | 81 |
| <i>TABLE 67 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%)</i> | 82 |
| <i>TABLE 68 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%)</i> | 82 |
| <i>TABLE 69 GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%)</i> | 83 |

| TOPIC | PAGE NO. |
|--|-----------------|
| TABLE 70 GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 | 83 |
| TABLE 71 CLINICAL TRIALS FOR BIPOLAR DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES | 84 |
| Patents | 84 |
| TABLE 72 NEUROSTIMULATION AND BIPOLAR DISORDER PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 85 |
| Depression | 85 |
| TABLE 73 DISTRIBUTION OF RANKINGS FOR DEPRESSION BY REGION, 2010 (RANK) | 85 |
| TABLE 74 GLOBAL PREVALENCE OF DEPRESSION, 2004 (MILLIONS) | 86 |
| FIGURE 28 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%) | 86 |
| FIGURE 29 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%) | 87 |
| FIGURE 30 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%) | 88 |
| TABLE 75 GLOBAL DEATHS DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 89 |
| TABLE 76 GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 90 |
| TABLE 77 GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC, 2010 (%) | 90 |
| TABLE 78 PREMARKET APPROVALS FOR DEPRESSION-ASSOCIATED NEUROSTIMULATION DEVICES | 91 |
| TABLE 79 CLINICAL TRIALS FOR DEPRESSION-ASSOCIATED NEUROSTIMULATION DEVICES | 91 |
| Patents | 92 |
| TABLE 80 NEUROSTIMULATION AND DEPRESSION PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 92 |
| NEUROSTIMULATION FOR STROKE AND TRAUMATIC BRAIN INJURY | 92 |
| STROKE | 92 |
| TABLE 81 RANKING OF MORTALITY DUE TO STROKE IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010 | 93 |
| TABLE 82 GLOBAL PREVALENCE OF STROKE BY COUNTRY, 2004 (MILLIONS) | 94 |
| TABLE 83 CLINICAL TRIALS FOR STROKE-ASSOCIATED NEUROSTIMULATION DEVICES | 95 |
| Patents | 95 |
| TABLE 84 NEUROSTIMULATION AND STROKE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 95 |
| TRAUMATIC BRAIN INJURY | 96 |
| FIGURE 31 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION IN MALES AND FEMALES IN THE U.S., 1997 TO 2007 (NUMBER) | 96 |
| FIGURE 32 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007 (NUMBER) | 97 |
| FIGURE 33 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35-85 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007 (NUMBER) | 97 |
| FIGURE 34 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007 (NUMBER) | 98 |
| FIGURE 35 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35 TO 85 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007 (NUMBER) | 99 |
| TABLE 85 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY ETHNICITY IN THE U.S., 1997 TO 2007 | 101 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 86 CLINICAL TRIALS FOR TRAUMATIC BRAIN INJURY-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 101 |
| Patents | 101 |
| <i>TABLE 87 NEUROSTIMULATION AND TRAUMATIC BRAIN INJURY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013</i> | 102 |
| NEUROSTIMULATION FOR CARDIOVASCULAR DISORDERS | 102 |
| HEART FAILURE | 102 |
| <i>FIGURE 36 DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN MALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008</i> | 102 |
| <i>FIGURE 37 DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN FEMALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008 (%)</i> | 103 |
| <i>FIGURE 38 GLOBAL DISTRIBUTION OF DEATHS IN THE MALE POPULATION BY LEADING CAUSE GROUP, 2004 (%)</i> | 104 |
| <i>FIGURE 39 GLOBAL DISTRIBUTION OF DEATHS IN THE FEMALE POPULATION BY LEADING CAUSE GROUP, 2004 (%)</i> | 105 |
| <i>TABLE 88 CLINICAL TRIALS FOR HEART FAILURE-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 106 |
| Patents | 106 |
| <i>TABLE 89 NEUROSTIMULATION AND HEART FAILURE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013</i> | 106 |
| NEUROSTIMULATION FOR GASTROINTESTINAL DISORDERS | 107 |
| GASTRIC DYSMOTILITY | 107 |
| <i>TABLE 90 CE MARK FOR GASTRO-ESOPHAGEAL REFLUX DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 107 |
| <i>TABLE 91 CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 107 |
| Patents | 108 |
| <i>TABLE 92 NEUROSTIMULATION AND GASTRIC DYSMOTILITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013</i> | 108 |
| GASTROPARESIS | 108 |
| <i>TABLE 93 GLOBAL DISTRIBUTION OF DEATHS IN THE MALE POPULATION BY LEADING CAUSE GROUP, 2004 (%)</i> | 109 |
| <i>TABLE 94 GLOBAL DISTRIBUTION OF DEATHS IN THE FEMALE POPULATION BY LEADING CAUSE GROUP, 2004 (%)</i> | 109 |
| <i>TABLE 95 PREMARKET APPROVALS FOR GASTROPARESIS-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 110 |
| <i>TABLE 96 CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES</i> | 110 |
| Patents | 110 |
| <i>TABLE 97 NEUROSTIMULATION AND GASTROPARESIS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013</i> | 111 |
| OBESITY | 111 |
| <i>TABLE 98 OBESITY IN MALES (>20 YEARS) BY GLOBAL REGION, 2008 (%)</i> | 111 |
| <i>TABLE 99 OBESITY IN FEMALES (>20 YEARS) BY GLOBAL REGION, 2008</i> | 111 |
| <i>TABLE 100 DISTRIBUTION OF OBESITY IN U.S. ADULTS (A) AND MALES (B) AS A PERCENTAGE OF TOTAL POPULATION BY AGE GROUP, 2009 TO 2010</i> | 112 |
| <i>TABLE 101 DISTRIBUTION OF OBESITY IN U.S. FEMALES AS A PERCENTAGE OF TOTAL POPULATION, ACCORDING TO AGE GROUP 2009-2010 (%)</i> | 112 |
| <i>TABLE 102 OBESITY AMONG MALES (>20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008 (%)</i> | 113 |

| TOPIC | PAGE NO. |
|---|-----------------|
| TABLE 103 OBESITY AMONG FEMALES (>20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008 (%) | 113 |
| TABLE 104 DISTRIBUTION OF OBESITY IN U.S. ADOLESCENTS AND CHILDREN AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 | 113 |
| TABLE 105 DISTRIBUTION OF OBESITY IN U.S. BOYS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 | 114 |
| TABLE 106 DISTRIBUTION OF OBESITY IN U.S. GIRLS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 | 114 |
| TABLE 107 CLINICAL TRIALS FOR OBESITY-ASSOCIATED NEUROSTIMULATION DEVICES | 115 |
| Patents | 115 |
| TABLE 108 NEUROSTIMULATION AND OBESITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 115 |
| NEUROSTIMULATION FOR URINARY AND RECTAL DISORDERS | 115 |
| URINARY INCONTINENCE | 115 |
| TABLE 109 PREMARKET APPROVALS FOR OVERACTIVE BLADDER DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES | 116 |
| TABLE 110 CLINICAL TRIALS FOR URINARY INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES | 116 |
| Patents | 117 |
| TABLE 111 NEUROSTIMULATION AND URINARY INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 117 |
| Fecal Incontinence | 117 |
| TABLE 112 PREMARKET APPROVALS FOR FECAL INCONTINENCE- ASSOCIATED NEUROSTIMULATION DEVICES | 118 |
| TABLE 113 CLINICAL TRIALS FOR FECAL INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES | 118 |
| Patents | 119 |
| TABLE 114 NEUROSTIMULATION AND FECAL INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 119 |
| NEUROSTIMULATION FOR SENSORY DISORDERS | 119 |
| HEARING LOSS (COCHLEAR NERVE STIMULATION) | 119 |
| TABLE 115 DISTRIBUTION OF RANKINGS FOR HEARING LOSS BY REGION, 2010 | 120 |
| TABLE 16 NEUROSTIMULATION AND PAIN PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 120 |
| TABLE 117 GLOBAL PREVALENCE OF MILD OR GREATER HEARING LOSS DISEASE, 2004 (\$ MILLIONS) | 121 |
| TABLE 118 LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY IN MALES, 2004 (MILLIONS) | 121 |
| TABLE 119 LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY IN FEMALES, 2004 (MILLIONS) | 122 |
| TABLE 120 PREMARKET APPROVALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES | 123 |
| TABLE 121 CLINICAL TRIALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES | 123 |
| Patents | 123 |
| TABLE 122 NEUROSTIMULATION AND HEARING LOSS PATENTS APPLIED FOR AND ISSUED FROM 2003-NOV. 30, 2013 | 123 |
| Tinnitus | 124 |
| TABLE 123 CLINICAL TRIALS FOR TINNITUS-ASSOCIATED NEUROSTIMULATION DEVICES | 124 |

| TOPIC | PAGE NO. |
|---|-----------------|
| Patents | 124 |
| <i>TABLE 124 NEUROSTIMULATION AND TINNITUS PATENTS APPLIED FOR AND ISSUED FROM 2003-NOV. 30, 2013</i> | 125 |
| ADAPTIVE NEUROSTIMULATION THERAPY | 125 |
| <i>TABLE 125 CLINICAL TRIALS FOR ADAPTIVE NEUROSTIMULATION TECHNOLOGY</i> | 126 |
| CHAPTER 5 COMPANY PROFILES | 128 |
| ADVANCED BIONICS, LLC | 128 |
| ALEVA NEUROTHERAPEUTICS SA | 128 |
| ATROTECH OY | 128 |
| AUTONOMIC TECHNOLOGIES INC. | 129 |
| AVERY BIOMEDICAL DEVICES INC. | 129 |
| BIONESS INC. | 129 |
| BIOTRONIK SE & CO. KG | 130 |
| BOSTON SCIENTIFIC CORP. | 130 |
| CERBOMED GMBH | 131 |
| COCHLEAR AMERICAS | 131 |
| CVRX INC. | 131 |
| CYBERONICS INC. | 132 |
| ENTEROMEDICS INC. | 132 |
| MED-EL MEDICAL ELECTRONICS | 133 |
| MEDTRONIC INC. | 133 |
| NEUROMETRIX INC. | 134 |
| NEURONETICS INC. | 134 |
| NEUROPACE INC. | 134 |
| NEUROSIGMA | 135 |
| NEVRO CORP. | 135 |
| SECOND SIGHT MEDICAL PRODUCTS INC. | 135 |
| SPINAL MODULATION INC. | 136 |
| SPR THERAPEUTICS LLC | 136 |
| ST. JUDE MEDICAL | 137 |
| UROPLASTY INC. | 138 |
| ZYNEX MEDICAL INC. | 138 |

LIST OF TABLES

| TABLE HEADING | PAGE NO. |
|--|-----------------|
| SUMMARY TABLE GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY, THROUGH 2018 (\$ MILLIONS) | 8 |
| TABLE 1 CHRONIC PAIN NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS) | 10 |
| TABLE 2 HEARING LOSS NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS) | 13 |
| TABLE 3 OVERACTIVE BLADDER NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS) | 14 |
| TABLE 4 EPILEPSY NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS) | 15 |
| TABLE 5 FOOT DROP NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS) | 16 |
| TABLE 6 GASTROINTESTINAL DISORDERS NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS) | 18 |
| TABLE 7 RETINAL DEGENERATION NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (\$ MILLIONS) | 20 |
| TABLE 8 PREMARKET APPROVALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES | 28 |
| TABLE 9 PREMARKET NOTIFICATIONS (510K) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES | 29 |
| TABLE 10 CLINICAL TRIALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES | 29 |
| TABLE 11 CLINICAL TRIALS UNDERWAY FOR CHRONIC MIGRAINE-ASSOCIATED NEUROSTIMULATION DEVICES | 32 |
| TABLE 12 PREMARKET APPROVALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES | 33 |
| TABLE 13 CLINICAL TRIALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES | 33 |
| TABLE 14 PREMARKET APPROVALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES | 34 |
| TABLE 15 CLINICAL TRIALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES | 34 |
| TABLE 16 NEUROSTIMULATION AND PAIN PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 35 |
| TABLE 17 PREMARKET APPROVALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES | 43 |
| TABLE 18 CLINICAL TRIALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES | 43 |
| TABLE 19 PATENTS FOR NEUROSTIMULATION AND PARKINSON'S APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 (NUMBER) | 44 |
| TABLE 20 PREMARKET APPROVALS FOR DYSTONIA-ASSOCIATED NEUROSTIMULATION DEVICES | 45 |
| TABLE 21 CLINICAL TRIALS FOR DYSTONIA-ASSOCIATED DEEP NEUROSTIMULATION DEVICES | 45 |
| TABLE 22 NEUROSTIMULATION AND DYSTONIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 (NUMBER) | 46 |
| TABLE 23 PREMARKET APPROVALS FOR ESSENTIAL TREMOR-ASSOCIATED NEUROSTIMULATION DEVICES | 46 |
| TABLE 24 CLINICAL TRIALS FOR ESSENTIAL TREMOR-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES | 47 |

| TABLE HEADING | PAGE NO. |
|--|-----------------|
| TABLE 25 NEUROSTIMULATION AND ESSENTIAL TREMOR PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 (NUMBER) | 47 |
| TABLE 26 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS, 2005 (%) | 48 |
| TABLE 27 GLOBAL DISTRIBUTION OF RANKINGS FOR EPILEPSY BY REGION, 2010 | 48 |
| TABLE 28 GLOBAL PREVALENCE OF EPILEPSY (MILLIONS) | 49 |
| TABLE 29 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2005 | 49 |
| TABLE 30 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2005 (%) | 50 |
| TABLE 31 GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, 2004 (%) | 52 |
| TABLE 32 GLOBAL DEATHS OF MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2004 (%) | 52 |
| TABLE 33 GLOBAL DEATHS OF FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2004 (%) | 53 |
| TABLE 34 PREMARKET APPROVALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES | 54 |
| TABLE 35 PREMARKET NOTIFICATION (510K) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES | 54 |
| TABLE 36 CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES | 54 |
| TABLE 37 CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED VAGAL NERVE NEUROSTIMULATION DEVICES | 54 |
| TABLE 38 NEUROSTIMULATION AND EPILEPSY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 (NUMBER) | 55 |
| TABLE 39 GLOBAL DEATHS IN THE MALE POPULATION BY LEADING CAUSE GROUP, 2004 (%) | 56 |
| TABLE 40 GLOBAL DEATHS IN THE FEMALE POPULATION BY LEADING CAUSE GROUP, 2004 (%) | 56 |
| TABLE 41 GLOBAL RANKING OF SCHIZOPHRENIA BY REGION, 2010 | 58 |
| TABLE 42 GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING SCHIZOPHRENIA, 2010 (%) | 63 |
| TABLE 43 GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 63 |
| TABLE 44 GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 64 |
| TABLE 45 CLINICAL TRIALS FOR SCHIZOPHRENIA-ASSOCIATED NEUROSTIMULATION DEVICES | 65 |
| TABLE 46 NEUROSTIMULATION AND SCHIZOPHRENIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 65 |
| TABLE 47 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%) | 66 |
| TABLE 48 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%) | 67 |
| TABLE 49 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%) | 67 |
| TABLE 50 DISTRIBUTION OF DALYS FOR OCD IN MALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006 | 68 |
| TABLE 51 DISTRIBUTION OF DALYS FOR OCD IN FEMALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006 | 68 |

| TABLE HEADING | PAGE NO. |
|--|-----------------|
| TABLE 52 CLINICAL TRIALS FOR OCD-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES | 68 |
| TABLE 53 CLINICAL TRIALS FOR TOURETTE SYNDROME-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES | 69 |
| TABLE 54 NEUROSTIMULATION AND OCD PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 70 |
| TABLE 55 GLOBAL PREVALENCE OF ALZHEIMER'S DISEASE, 2006 (MILLIONS) | 70 |
| TABLE 56 RANKING OF MORTALITY DUE TO ALZHEIMER'S IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010 | 71 |
| TABLE 57 GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 74 |
| TABLE 58 GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 76 |
| TABLE 59 GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 76 |
| TABLE 60 CLINICAL TRIALS FOR ALZHEIMER'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES | 77 |
| TABLE 61 NEUROSTIMULATION AND ALZHEIMER'S PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 78 |
| TABLE 62 CLINICAL TRIALS FOR ANOREXIA NERVOSA-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES | 79 |
| TABLE 63 NEUROSTIMULATION AND ANOREXIA NERVOSA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 79 |
| TABLE 64 DISTRIBUTION OF RANKINGS FOR BIPOLAR DISORDER BY GLOBAL REGIONS, 2010 (RANK) | 80 |
| TABLE 65 GLOBAL PREVALENCE OF BIPOLAR DISORDER, 2004 (MILLIONS) | 81 |
| TABLE 66 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 | 81 |
| TABLE 67 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%) | 82 |
| TABLE 68 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%) | 82 |
| TABLE 69 GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 83 |
| TABLE 70 GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 | 83 |
| TABLE 71 CLINICAL TRIALS FOR BIPOLAR DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES | 84 |
| TABLE 72 NEUROSTIMULATION AND BIPOLAR DISORDER PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 85 |
| TABLE 73 DISTRIBUTION OF RANKINGS FOR DEPRESSION BY REGION, 2010 (RANK) | 85 |
| TABLE 74 GLOBAL PREVALENCE OF DEPRESSION, 2004 (MILLIONS) | 86 |
| TABLE 75 GLOBAL DEATHS DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 89 |
| TABLE 76 GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, 2010 (%) | 90 |
| TABLE 77 GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC, 2010 (%) | 90 |
| TABLE 78 PREMARKET APPROVALS FOR DEPRESSION-ASSOCIATED NEUROSTIMULATION DEVICES | 91 |
| TABLE 79 CLINICAL TRIALS FOR DEPRESSION-ASSOCIATED NEUROSTIMULATION DEVICES | 91 |
| TABLE 80 NEUROSTIMULATION AND DEPRESSION PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 92 |

| TABLE HEADING | PAGE NO. |
|---|-----------------|
| TABLE 81 RANKING OF MORTALITY DUE TO STROKE IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010 | 93 |
| TABLE 82 GLOBAL PREVALENCE OF STROKE BY COUNTRY, 2004 (MILLIONS) | 94 |
| TABLE 83 CLINICAL TRIALS FOR STROKE-ASSOCIATED NEUROSTIMULATION DEVICES | 95 |
| TABLE 84 NEUROSTIMULATION AND STROKE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 95 |
| TABLE 85 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY ETHNICITY IN THE U.S., 1997 TO 2007 | 101 |
| TABLE 86 CLINICAL TRIALS FOR TRAUMATIC BRAIN INJURY-ASSOCIATED NEUROSTIMULATION DEVICES | 101 |
| TABLE 87 NEUROSTIMULATION AND TRAUMATIC BRAIN INJURY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 102 |
| TABLE 88 CLINICAL TRIALS FOR HEART FAILURE-ASSOCIATED NEUROSTIMULATION DEVICES | 106 |
| TABLE 89 NEUROSTIMULATION AND HEART FAILURE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 106 |
| TABLE 90 CE MARK FOR GASTRO-ESOPHAGEAL REFLUX DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES | 107 |
| TABLE 91 CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES | 107 |
| TABLE 92 NEUROSTIMULATION AND GASTRIC DYSMOTILITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 108 |
| TABLE 93 GLOBAL DISTRIBUTION OF DEATHS IN THE MALE POPULATION BY LEADING CAUSE GROUP, 2004 (%) | 109 |
| TABLE 94 GLOBAL DISTRIBUTION OF DEATHS IN THE FEMALE POPULATION BY LEADING CAUSE GROUP, 2004 (%) | 109 |
| TABLE 95 PREMARKET APPROVALS FOR GASTROPARESIS-ASSOCIATED NEUROSTIMULATION DEVICES | 110 |
| TABLE 96 CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES | 110 |
| TABLE 97 NEUROSTIMULATION AND GASTROPARESIS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 111 |
| TABLE 98 OBESITY IN MALES (>20 YEARS) BY GLOBAL REGION, 2008 (%) | 111 |
| TABLE 99 OBESITY IN FEMALES (>20 YEARS) BY GLOBAL REGION, 2008 | 111 |
| TABLE 100 DISTRIBUTION OF OBESITY IN U.S. ADULTS (A) AND MALES (B) AS A PERCENTAGE OF TOTAL POPULATION BY AGE GROUP, 2009 TO 2010 | 112 |
| TABLE 101 DISTRIBUTION OF OBESITY IN U.S. FEMALES AS A PERCENTAGE OF TOTAL POPULATION, ACCORDING TO AGE GROUP 2009-2010 (%) | 112 |
| TABLE 102 OBESITY AMONG MALES (>20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008 (%) | 113 |
| TABLE 103 OBESITY AMONG FEMALES (>20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008 (%) | 113 |
| TABLE 104 DISTRIBUTION OF OBESITY IN U.S. ADOLESCENTS AND CHILDREN AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 | 113 |
| TABLE 105 DISTRIBUTION OF OBESITY IN U.S. BOYS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 | 114 |
| TABLE 106 DISTRIBUTION OF OBESITY IN U.S. GIRLS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 | 114 |
| TABLE 107 CLINICAL TRIALS FOR OBESITY-ASSOCIATED NEUROSTIMULATION DEVICES | 115 |
| TABLE 108 NEUROSTIMULATION AND OBESITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 115 |

| TABLE HEADING | PAGE NO. |
|---|-----------------|
| TABLE 109 PREMARKET APPROVALS FOR OVERACTIVE BLADDER DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES | 116 |
| TABLE 110 CLINICAL TRIALS FOR URINARY INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES | 116 |
| TABLE 111 NEUROSTIMULATION AND URINARY INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 117 |
| TABLE 112 PREMARKET APPROVALS FOR FECAL INCONTINENCE- ASSOCIATED NEUROSTIMULATION DEVICES | 118 |
| TABLE 113 CLINICAL TRIALS FOR FECAL INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES | 118 |
| TABLE 114 NEUROSTIMULATION AND FECAL INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 119 |
| TABLE 115 DISTRIBUTION OF RANKINGS FOR HEARING LOSS BY REGION, 2010 | 120 |
| TABLE 16 NEUROSTIMULATION AND PAIN PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOV. 30, 2013 | 120 |
| TABLE 117 GLOBAL PREVALENCE OF MILD OR GREATER HEARING LOSS DISEASE, 2004 (\$ MILLIONS) | 121 |
| TABLE 118 LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY IN MALES, 2004 (MILLIONS) | 121 |
| TABLE 119 LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY IN FEMALES, 2004 (MILLIONS) | 122 |
| TABLE 120 PREMARKET APPROVALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES | 123 |
| TABLE 121 CLINICAL TRIALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES | 123 |
| TABLE 122 NEUROSTIMULATION AND HEARING LOSS PATENTS APPLIED FOR AND ISSUED FROM 2003-NOV. 30, 2013 | 123 |
| TABLE 123 CLINICAL TRIALS FOR TINNITUS-ASSOCIATED NEUROSTIMULATION DEVICES | 124 |
| TABLE 124 NEUROSTIMULATION AND TINNITUS PATENTS APPLIED FOR AND ISSUED FROM 2003-NOV. 30, 2013 | 125 |
| TABLE 125 CLINICAL TRIALS FOR ADAPTIVE NEUROSTIMULATION TECHNOLOGY | 126 |

LIST OF FIGURES

| FIGURE TITLE | PAGE NO. |
|---|-----------------|
| SUMMARY FIGURE GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY, 2012-2018 (\$ MILLIONS) | 8 |
| FIGURE 1 MARKET SHARE OF CHRONIC PAIN NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (%) | 11 |
| FIGURE 2 MARKET SHARES OF HEARING LOSS NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (%) | 13 |
| FIGURE 3 MARKET SHARES OF GASTROINTESTINAL DISORDERS NEUROSTIMULATION DEVICE SALES BY MANUFACTURER, 2012 (%) | 18 |
| FIGURE 4 DISTRIBUTION OF CHRONIC BACK PAIN INJURY/ILLNESS REQUIRING DAYS MISSED FROM WORK BY CONDITION, 2011 (INCIDENCE RATE) | 24 |
| FIGURE 5 DISTRIBUTION OF SPRAINS, STRAINS AND TEARS REQUIRING ABSENCES FROM WORK BY BODY PART, 2011 (%) | 25 |
| FIGURE 6 DISTRIBUTION OF BACK INJURY INCIDENT RATES BY AGE GROUP, 2011 | 26 |
| FIGURE 7 DISTRIBUTION OF INCIDENCE RATES OF SORENESS INCLUDING BACK PAIN BY AGE GROUP, 2011 | 27 |
| FIGURE 8 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS INCLUDING MIGRAINE, 2005 (%) | 30 |
| FIGURE 9 DISTRIBUTION OF MIGRAINE INCIDENCE RATES BY AGE GROUP, 2011 | 31 |
| FIGURE 10 GLOBAL PREVALENCE OF PARKINSON'S DISEASE, 2010 (MILLIONS) | 35 |
| FIGURE 11 GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, 2004 (%) | 36 |
| FIGURE 12 GLOBAL DEATHS OF MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, 2004 (%) | 37 |
| FIGURE 13 GLOBAL DEATHS OF FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, 2004 (%) | 38 |
| FIGURE 14 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2005 (%) | 39 |
| FIGURE 15 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2005 (%) | 40 |
| FIGURE 16 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2005 (%) | 41 |
| FIGURE 17 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2005 (%) | 42 |
| FIGURE 18 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2005 | 50 |
| FIGURE 19 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006 (%) | 57 |
| FIGURE 20 GLOBAL PREVALENCE OF SCHIZOPHRENIA, 2004 (%) | 58 |
| FIGURE 21 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%) | 59 |
| FIGURE 22 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%) | 60 |
| FIGURE 23 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%) | 61 |
| FIGURE 24 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%) | 71 |
| FIGURE 25 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%) | 72 |
| FIGURE 26 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%) | 73 |

| FIGURE TITLE | PAGE NO. |
|---|-----------------|
| FIGURE 27 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006 (%) | 75 |
| FIGURE 28 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%) | 86 |
| FIGURE 29 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%) | 87 |
| FIGURE 30 DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS AS A PERCENTAGE OF TOTAL DALYS, 2006 (%) | 88 |
| FIGURE 31 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION IN MALES AND FEMALES IN THE U.S., 1997 TO 2007 (NUMBER) | 96 |
| FIGURE 32 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007 (NUMBER) | 97 |
| FIGURE 33 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35-85 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007 (NUMBER) | 97 |
| FIGURE 34 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007 (NUMBER) | 98 |
| FIGURE 35 TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35 TO 85 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007 (NUMBER) | 99 |
| FIGURE 36 DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN MALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008 | 102 |
| FIGURE 37 DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN FEMALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008 (%) | 103 |
| FIGURE 38 GLOBAL DISTRIBUTION OF DEATHS IN THE MALE POPULATION BY LEADING CAUSE GROUP, 2004 (%) | 104 |
| FIGURE 39 GLOBAL DISTRIBUTION OF DEATHS IN THE FEMALE POPULATION BY LEADING CAUSE GROUP, 2004 (%) | 105 |